MedTrace Logo

Resveratrol for Exudative Age-Related Macular Degeneration

NCT02625376 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-06-01

No results posted yet for this study

Summary

This is an interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.

Conditions

  • AMD
  • Age-related Macular Degeneration
  • Choroidal Neovascularisation

Interventions

DIETARY_SUPPLEMENT

Resvega

Dietary supplementation with Resvega BD

DIETARY_SUPPLEMENT

Trans-Resveratrol

Dietary supplementation with resveratrol 250 mg BD

DIETARY_SUPPLEMENT

placebo

Dietary supplementation with a placebo BD

Sponsors & Collaborators

  • Poitiers University Hospital

    lead OTHER

Principal Investigators

  • Nicolas LEVEZIEL, MD, PhD · Dpt of Ophthalmology, University Hospital of Poitiers, France

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-06
Primary Completion
2016-10-26
Completion
2016-11-09

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02625376 on ClinicalTrials.gov